BNP Measurement Reduces Resource Utilization for Patients With CHF Admitted Thorough the ED

Mayo Clinic

Status: Completed

Conditions: Congestive Heart Failure

Study type: Observational

Funder types: Other

Identifiers

NCT00587938

1780-03

Details and patient eligibility

About

Measurement of brain natriuretic peptide (BNP) in dyspneic patients increases diagnostic accuracy for congestive heart failure (CHF). Limited information is available regarding economic outcomes attributable to BNP assay. The aim of this study was to assess the economic impact of BNP assay in elderly dyspneic patients presenting to the emergency department (ED).

Full description

Dyspneic patients 65 years were enrolled in a randomized, controlled trial; hemodynamically unstable patients were excluded. BNP (Biosite assay) levels were measured prior to physician assessment with randomization in 1:1 ratio to either BNP 1) level reported or 2) level not reported. ED physicians made triage decisions guided by clinical judgment and nomogram to aid in interpretation of BNP level. Primary outcome was mean total hospital cost per subject. Secondary outcomes included admission rate, service assignment, discharge diagnosis and length of stay. Differences between groups were compared by t-test with bootstrap. Costs reflect 2005 constant dollars.

Enrollment: 200 patients

Sex: All

Ages: 65+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Dyspneic patients 65 years or older presenting to the ED with chief complaint of shortness of breath.

Exclusion criteria

• hemodynamically unstability

Trial design

200 participants in 2 patient groups

A

Description:

BNP level from protocol blood tests initiated in the ED, reported to ED physician prior to ED disposition.

B

Description:

BNP level from protocol blood tests initiated in the ED, NOT reported to ED physician prior to ED disposition.